RecruitingPhase 2NCT05940324

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)


Sponsor

Stanford University

Enrollment

150 participants

Start Date

Feb 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether the rapid antidepressant effects of ketamine (an anesthetic sometimes used for depression) in people with OCD (obsessive-compulsive disorder) are related to the opioid system in the brain. **You may be eligible if...** - You are between 18 and 65 years old - You have a confirmed diagnosis of OCD - Standard first-line treatments (such as therapy or certain medications) have not worked for you — you must have tried at least one - You are willing to fast before the experimental sessions - You are able to follow the study requirements **You may NOT be eligible if...** - You have a current substance use disorder or history of opioid use - You have certain other psychiatric conditions that could interfere with the study - You are pregnant or breastfeeding - You have serious medical conditions affecting the heart, liver, or kidneys - You are taking medications that interact with ketamine or naltrexone Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine

Ketamine is an FDA-approved dissociative anesthetic.

DRUGNaltrexone Pill

Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)

OTHERPlacebo pill

An oral inactive placebo pill will be administered to preserve the blinded nature of the study.


Locations(1)

Department of Psychiatry & Behavioral Sciences

Stanford, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05940324


Related Trials